文献速递眼底病与葡萄膜炎

钌-106敷贴放疗治疗局限性脉络膜血管瘤

RUTHENIUM-106 BRACHYTHERAPY IN THE TREATMENT OF CIRCUMSCRIBED CHOROIDAL HEMANGIOMA.
PubMed 文献 · Retina · 2018-01-01

研究纳入21例(21眼)症状性局限性脉络膜血管瘤患者,接受钌-106敷贴放疗。随访1年时12眼(57%)视力提高、7眼(33%)稳定、2眼(10%)下降,视网膜下液和黄斑囊样水肿全部消退,视力、肿瘤厚度、最大直径及中心凹下厚度变化均有统计学意义,作者结论为该方法有效且安全。

要点

  • 21眼症状性局限性脉络膜血管瘤接受钌-106敷贴放疗,1年时12眼(57%)视力提高。
  • 视网膜下液和黄斑囊样水肿在全部患者中消退。
  • 放射性视网膜病变5眼(24%)、放射性视乳头病变1眼(5%)、视网膜下纤维化2眼(10%)。

核心结论

  • 作者结论认为钌-106敷贴放疗是治疗症状性局限性脉络膜血管瘤有效且安全的方法。
  • 作者指出及时处理并发症时永久性视力丧失的发生率低。

研究设计与样本

  • 研究纳入21例(21眼)诊断为症状性局限性脉络膜血管瘤并接受钌-106敷贴放疗的患者。
  • 研究评估临床反应、辅助检查改善情况及主要副作用。

主要发现

  • 从初诊至1年随访,视力提高12眼(57%)、稳定7眼(33%)、下降2眼(10%)。
  • 基于荧光素血管造影和光学相干断层扫描,视网膜下液和黄斑囊样水肿在全部患者中消退。
  • 最小分辨角对数视力变化P=0.038,超声检查肿瘤厚度变化P=0.0001、最大直径变化P=0.007,光学相干断层扫描中心凹下厚度变化P<0.0001,初诊与1年随访间差异均有统计学意义。
  • 随访期间副作用包括放射性视网膜病变5眼(24%)、放射性视乳头病变1眼(5%)、视网膜下纤维化2眼(10%)。
  • 视网膜下纤维化是唯一永久性放射相关副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the efficacy and safety of Ruthenium-106 plaque radiotherapy in the treatment of circumscribed choroidal hemangioma. METHODS: Twenty-one eyes of 21 patients diagnosed with symptomatic circumscribed choroidal hemangioma who underwent Ruthenium-106 plaque radiotherapy were included in the study. Clinical response, ancillary tests finding improvement, and major side effects were evaluated. RESULTS: From the initial to the 1-year follow-up visits, vision improved in 12 eyes (57%), was stable in 7 eyes (33%), and became worse in 2 eyes (10%). Based on fluorescein angiography and optical coherence tomography, subretinal fluid and cystoid macular edema resolved in all patients. Changes in logarithm of minimum angle of resolution visual acuity (P = 0.038); tumor thickness (P = 0.0001) and largest diameter (P = 0.007) on ultrasonography; and subfoveal thickness on optical coherence tomography (P < 0.0001), were statistically significant between the initial and the 1-year follow-up visits. Side effects as observed during the follow-up period included: radiation-related retinopathy in 5 (24%) eyes, radiation-related papillopathy in 1 eye (5%), and subretinal fibrosis in 2 eyes (10%). Subretinal fibrosis was the only permanent radiation-related side effect. CONCLUSION: Ruthenium-106 plaque radiotherapy is an effective and safe method of treatment for symptomatic circumscribed choroidal hemangiomas. The incidence of permanent visual loss is low with prompt treatment of complications.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Naseripour M, Maleki A, Astaraki A, et al. RUTHENIUM-106 BRACHYTHERAPY IN THE TREATMENT OF CIRCUMSCRIBED CHOROIDAL HEMANGIOMA. Retina. 2018. PMID: 28338557. doi:10.1097/IAE.0000000000001616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。